Abstract
β-secretase (BACE-1) plays a pivotal role in the β-Amyloid plaques formation, which is responsible for progressive cognitive and memory loss commonly found in Alzheimer disease patients. As a consequence, it has been considered as a good target for drug development efforts. Early work focused on the synthesis of peptidomimetics, but poor pharmacokinetics profile prevented advancing lead compounds to clinical trials. As an alternative, aminoimidazoles, aminohydantoins and aminopyridines derivatives that inhibit BACE-1 were designed. Herein we report statistically sound descriptor- based (r2 = 0.87, q2 = 0.85, 6 PCs) and fragment-based (r2 = 0.91, q2 = 0.84, 6 PCs) QSAR models, that show high predictive ability (r2 pred = 0.84, averaged r2 m=0.78) and underscore polar interactions that are important for BACE-1 inhibition.
Keywords: Alzheimer, β-Amyloid, Beta-secretase (BACE-1), 2D-QSAR, Hologram QSAR.
Medicinal Chemistry
Title:2D QSAR Studies on Series of Human Beta-secretase (BACE-1) Inhibitors
Volume: 10 Issue: 2
Author(s): Daniela Santos Cruz and Marcelo Santos Castilho
Affiliation:
Keywords: Alzheimer, β-Amyloid, Beta-secretase (BACE-1), 2D-QSAR, Hologram QSAR.
Abstract: β-secretase (BACE-1) plays a pivotal role in the β-Amyloid plaques formation, which is responsible for progressive cognitive and memory loss commonly found in Alzheimer disease patients. As a consequence, it has been considered as a good target for drug development efforts. Early work focused on the synthesis of peptidomimetics, but poor pharmacokinetics profile prevented advancing lead compounds to clinical trials. As an alternative, aminoimidazoles, aminohydantoins and aminopyridines derivatives that inhibit BACE-1 were designed. Herein we report statistically sound descriptor- based (r2 = 0.87, q2 = 0.85, 6 PCs) and fragment-based (r2 = 0.91, q2 = 0.84, 6 PCs) QSAR models, that show high predictive ability (r2 pred = 0.84, averaged r2 m=0.78) and underscore polar interactions that are important for BACE-1 inhibition.
Export Options
About this article
Cite this article as:
Cruz Santos Daniela and Castilho Santos Marcelo, 2D QSAR Studies on Series of Human Beta-secretase (BACE-1) Inhibitors, Medicinal Chemistry 2014; 10 (2) . https://dx.doi.org/10.2174/15734064113099990002
DOI https://dx.doi.org/10.2174/15734064113099990002 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microcapsules of Cajá-manga (Spondias dulcis Parkinson): Influence of Different Types of Encapsulating Agents and Drying Technology
Current Nutrition & Food Science Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms
Current Molecular Medicine CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Current Molecular Medicine A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review
Current Cancer Drug Targets Influence of Different Substituents on Anion Binding Ability in Aromatic Hydroxyl Group Derivatives: Experiment and Theory
Current Analytical Chemistry Emerging Signalling and Protein Interactions Mediated Via Metabotropic Glutamate Receptors
Current Drug Targets - CNS & Neurological Disorders Postmortem-Assessed Impairment of Neuronal Activity in Depression: The Dominant Impact of Suicide
CNS & Neurological Disorders - Drug Targets Angelica Injection Reduces Cognitive Impairment during Chronic Cerebral Hypoperfusion through Brain-Derived Neurotrophic Factor and Nerve Growth Factor
Current Neurovascular Research Lisdexamfetamine Alters BOLD-fMRI Activations Induced by Odor Cues in Impulsive Children
CNS & Neurological Disorders - Drug Targets Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Neuroprotection in Glaucoma Using Calpain-1 Inhibitors: Regional Differences in Calpain-1 Activity in the Trabecular Meshwork, Optic Nerve and Implications for Therapeutics
CNS & Neurological Disorders - Drug Targets Budesonide: Teaching an Old Dog New Tricks for Inflammatory Bowel Disease Treatment
Current Medicinal Chemistry Strategic Paradigm Shifts in the Antimicrobial Drug Discovery Process of the 21st Century
Infectious Disorders - Drug Targets Effect of HPMC - E15 LV premium Polymer on Release Profile and Compression Characteristics of Chitosan/ Pectin Colon Targeted Mesalamine Matrix Tablets and in vitro Study on Effect of pH Impact on the Drug Release Profile
Recent Patents on Drug Delivery & Formulation Editorial [The Trifluoromethyl Group in Organic Synthesis: Recent Developments (Guest Editor: Simon E. Lopez)]
Current Organic Synthesis Mechanism of Action and Potential Use of Tamoxifen in the Treatment of Acute Mania
Current Psychopharmacology Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer’s Disease in the Transgenic CRND8 Mice
Current Alzheimer Research Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Extrasynaptic GABA and Glutamate Receptors in Epilepsy
CNS & Neurological Disorders - Drug Targets Recent Patents Concerning Targeted Therapy of Apoptosis Resistance in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences